Biological
PEGylated Recombinant Factor VIII
PEGylated Recombinant Factor VIII is a biological therapy with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
83%(5 trials)
Phase Distribution
Ph phase_3
3
50%
Ph phase_2
1
17%
Ph phase_1
1
17%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_3
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
NCT02615691
completed
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.
NCT04941898
completedphase_3
BAX 855 PK-guided Dosing
NCT02585960
completedphase_3
BAX 855 Pediatric Study
NCT02210091
completedphase_2
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
NCT01736475
Clinical Trials (6)
Showing 6 of 6 trials
NCT02615691Phase 3
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
NCT04941898
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.
NCT02585960Phase 3
BAX 855 PK-guided Dosing
NCT02210091Phase 3
BAX 855 Pediatric Study
NCT01736475Phase 2
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
NCT01599819Phase 1
BAX 855 Dose-Escalation Safety Study
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6